AOA Dx is proud to announce that Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, in collaboration with Dr. Anne-Marie Mes-Masson of the Centre hospitalier de l’Université de Montréal (CHUM) were awarded a grant from the Réseau Québécois de Recherche sur les Médicaments (RQRM). The work supported by the grant is the first of many steps demonstrating that gangliosides are an accurate and reliable marker to detect early stage cancers, and that tumor-gangliosides can be exploited for diagnostics in liquid biopsies. This award further demonstrates that world-leading scientists, such as Prof. Saragovi and Dr. Mes-Masson, are getting ever closer to accurate early-stage cancer diagnosis.
”We are incredibly proud of Prof. Uri Saragovi and his talented team for obtaining this award. We are confident this research will lead to the availability of a cost-effective, simple and accurate diagnosis test, with further validation of the biomarkers,” says Anna Jeter, CBO at AOA Dx.
“This is a fantastic achievement and I am grateful to the RQRM for recognizing this important work. We look forward to sharing more of our research in the near future and contributing to the early diagnosis of early-stage cancers,” says Prof. Uri Saragovi.
About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at www.aoadx.com.